Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype
M. Kokosi (London, United Kingdom), A. Trachalaki (London, United Kingdom), C. Stock (London, United Kingdom), J. Donovan (London, United Kingdom), E. Tsitoura (Herakleion, Greece), V. Kouranos (Londonn, United Kingdom), P. George (Londonn, United Kingdom), P. Molyneaux (Londonn, United Kingdom), F. Chua (Londonn, United Kingdom), T. Maher (Londonn, United Kingdom), E. Renzoni (Londonn, United Kingdom), N. Tzanakis (Herakleion, Greece), A. Wells (London, United Kingdom), K. Antoniou (Herakleion, Greece)
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kokosi (London, United Kingdom), A. Trachalaki (London, United Kingdom), C. Stock (London, United Kingdom), J. Donovan (London, United Kingdom), E. Tsitoura (Herakleion, Greece), V. Kouranos (Londonn, United Kingdom), P. George (Londonn, United Kingdom), P. Molyneaux (Londonn, United Kingdom), F. Chua (Londonn, United Kingdom), T. Maher (Londonn, United Kingdom), E. Renzoni (Londonn, United Kingdom), N. Tzanakis (Herakleion, Greece), A. Wells (London, United Kingdom), K. Antoniou (Herakleion, Greece). Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype. 445
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: